Kane Biotech Inc(KNBIF)
USD --+0.00%
Reward52Moderate
Risk55Medium-High
📊75%Data
Revenue down 99% YoY
KNBIF
+0.0 · +0.00%
USD · PINK
Kane Biotech Inc | Healthcare
Profitless Growth
Market Cap:4.59M
ℹ️
Reward Rating
52
Moderate
Bottom 50% (model universe)
75% data coverage
ℹ️
Risk Rating
55
Medium-High
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on KNBIF to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Kane Biotech Inc?

, a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally.

KNBIF · Verdict

Moderate reward · elevated risk

KNBIF stands out on volatility and growth, but watch the balance sheet signal.

Based on 88% data coverage

KNBIF · Verdict

What’s working & what to watch

Strengths 2

  • Volatility95/100

    Top decile vs peers

  • Growth66/100

    Revenue +9.0% CAGR

Watchouts 4

  • Balance sheet23/100

    Current ratio 0.43

  • Profitability33/100

    293% net margin · -597% ROE

  • Cash flow39/100

    -202% free-cash-flow margin

  • Valuation41/100

    Below average

Model-based scoring. For information only — not financial advice.

What is Kane Biotech Inc?

, a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, a biofilm destabilizing formula with continuous activity; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine (PNAG) for treating wounds and otic infections. The company is listed on the PINK in USA, operating in the Healthcare sector, with a market capitalisation of 4.59M.

Financial Highlights

Investment Breakdown

📈 Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
💰 Profitability
Thin or inconsistent margins weigh on earnings quality.
⚠️ Risk
Moderate volatility with meaningful macro and earnings sensitivity.
💸 Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (52)

The scoring profile indicates limited reward potential at this time, with growth and momentum offering the most support. Risk indicators are elevated — volatility and macro sensitivity warrant consideration.

For informational purposes only. Not financial advice.

Company Information
SectorHealthcare
Market Cap4.59M
P/E RatioN/A
Dividend YieldN/A
52 Week High0.072
52 Week Low0.0218
Last AnnualDecember
IPO DateN/A
IncorporatedUSA
Shares Outstanding167M
No. of EmployeesN/A
IndustryBiotechnology
ExchangePINK
Beta0.148
CurrencyUSD · Reports in CAD